B.C. Premier Calls for Changes to Rare Disease Drug Funding

In British Columbia, no changes have been implemented in the funding process for drugs treating rare diseases, despite Premier David Eby expressing concerns five months ago. The premier indicated that the existing system was failing, particularly following public outcry over the treatment of Charleigh Pollock, a 10-year-old from Vancouver Island suffering from Batten disease, a neurodegenerative condition with no known cure.

The provincial government initially supported a recommendation from an expert committee to discontinue a treatment costing over $800,000 annually. However, due to escalating public pressure, they reversed this decision, citing support from U.S. experts. In response to inquiries from Postmedia News, the B.C. Health Ministry confirmed that a review of the drug funding process remains ongoing. Senior public affairs officer Calvin Cen stated, “We will have information to share once it’s complete,” but did not provide a timeline for its conclusion.

The internal review seeks to enhance the process for funding expensive drugs, aiming for better support for patients and families. The ministry’s goal is to create a system that is more transparent and responsive, ensuring that all stakeholders, including patients and decision-makers, are well-informed and equipped with necessary resources.

Officials acknowledged the need to improve public understanding of how the funding process operates. The ministry indicated that greater transparency could help build trust, ensuring patients and families feel heard throughout the decision-making process.

Following the government’s decision to reinstate treatment for Pollock, ten members of the 58-member provincial advisory committee resigned in protest, and none have returned or been replaced. Although affected subcommittees maintain enough members to form a quorum, the overall drug approval process continues as it has in the past, with the Health Ministry still responsible for funding approvals.

In July, Eby emphasized the necessity of reforms for the rare disease funding system, advocating for increased transparency and clearer communication. He noted that the current structure, which limits public engagement and restricts committee members from speaking to the media, has led to perceptions that politicians influence decisions regarding access to essential medicines.

“We have to figure out a way that works for the doctors and experts advising on whether or not a particular patient should receive a particular treatment,” Eby stated, insisting that the process should be transparent and comprehensible to the public. Health Minister Josie Osborne echoed this sentiment, remarking that transparency is vital for fostering trust with patients and families.

Investigative reports from Postmedia highlighted that many U.S. experts consulted by the B.C. government regarding the reinstatement of the costly treatment had ties to the pharmaceutical company producing the drug or to advocacy foundations. Furthermore, a government review conducted four years prior had already identified the need for improved transparency and communication in the funding process. The review predicted significant increases in spending on rare disease drugs, estimating costs could reach $600 million annually by the end of the decade.

Despite these findings, few recommendations from the earlier report have been enacted. While the Health Ministry claims that the “majority” of the report’s recommendations have been addressed, it pointed to only two completed initiatives: the creation of a web page designed to enhance transparency and the establishment of an appeal process. The report’s numerous recommendations for further transparency, including enhanced oversight and public engagement, remain largely unaddressed.

As the review continues, the future of B.C.’s approach to funding rare disease treatments remains uncertain, with patients and families watching closely for necessary reforms.